Castle Biosciences (NASDAQ:CSTL) Insider Sells $31,037.83 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 817 shares of the firm’s stock in a transaction dated Wednesday, February 4th. The stock was sold at an average price of $37.99, for a total transaction of $31,037.83. Following the sale, the insider owned 83,698 shares of the company’s stock, valued at $3,179,687.02. This trade represents a 0.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Castle Biosciences Stock Up 1.1%

CSTL opened at $32.75 on Friday. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28. The company’s 50-day moving average price is $39.36 and its two-hundred day moving average price is $29.72. The stock has a market cap of $955.97 million, a price-to-earnings ratio of -72.78 and a beta of 1.06. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02.

Institutional Trading of Castle Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of CSTL. AIGH Capital Management LLC bought a new position in Castle Biosciences in the 3rd quarter valued at $16,105,000. Braidwell LP raised its position in shares of Castle Biosciences by 125.3% in the second quarter. Braidwell LP now owns 822,735 shares of the company’s stock worth $16,800,000 after buying an additional 457,488 shares in the last quarter. Summit Partners Public Asset Management LLC bought a new stake in Castle Biosciences during the third quarter valued at $9,108,000. Millennium Management LLC grew its position in Castle Biosciences by 34.2% during the third quarter. Millennium Management LLC now owns 575,089 shares of the company’s stock worth $13,095,000 after buying an additional 146,692 shares in the last quarter. Finally, Bridgeway Capital Management LLC increased its stake in Castle Biosciences by 334.8% in the 3rd quarter. Bridgeway Capital Management LLC now owns 177,180 shares of the company’s stock worth $4,034,000 after acquiring an additional 136,430 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CSTL. Lake Street Capital boosted their price objective on Castle Biosciences from $35.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Weiss Ratings reiterated a “sell (d)” rating on shares of Castle Biosciences in a research note on Monday, December 29th. Robert W. Baird upped their price target on shares of Castle Biosciences from $39.00 to $41.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, February 2nd. Finally, Guggenheim boosted their target price on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a report on Monday, January 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Castle Biosciences currently has an average rating of “Moderate Buy” and an average target price of $47.14.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.